Na+ H+ exchanger-1: a link with atherogenesis?

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY Expert opinion on investigational drugs Pub Date : 2010-12-01 Epub Date: 2010-11-04 DOI:10.1517/13543784.2010.532123

Maria Sarigianni, Apostolos Tsapas, Dimitri P Mikhailidis, Martha Kaloyianni, George Koliakos, Larry Fliegel, Konstantinos Paletas

{"title":"Na+ H+ exchanger-1: a link with atherogenesis?","authors":"Maria Sarigianni, Apostolos Tsapas, Dimitri P Mikhailidis, Martha Kaloyianni, George Koliakos, Larry Fliegel, Konstantinos Paletas","doi":"10.1517/13543784.2010.532123","DOIUrl":null,"url":null,"abstract":"Importance of the field: The sodium/hydrogen exchanger-1 (NHE-1/SLC9A1) is a ubiquitous plasma membrane protein whose main role is maintenance of intracellular pH and volume. NHE-1 plays a role in atherogenesis; however, its clinical relevance has not yet been established.Areas covered in this review: We herein review the contribution of NHE-1 in atherogenesis (namely its effect on endothelial cells, monocytes, smooth muscle cells and platelets).What the reader will gain: Studies have shown that NHE is involved in atherogenesis-related properties of isolated monocytes. We also consider the relationship between NHE-1 and vascular risk factors such as obesity, diabetes mellitus, hypertension, dyslipidemia and inflammation.Take home message: Even though clinical trials with certain NHE-1 inhibitors have had discouraging results, NHE-1 cannot be excluded as a potential future therapeutic target for the prevention and/or treatment of atherosclerosis.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":"19 12","pages":"1545-56"},"PeriodicalIF":4.9000,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1517/13543784.2010.532123","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1517/13543784.2010.532123","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2010/11/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 14

Abstract

Importance of the field: The sodium/hydrogen exchanger-1 (NHE-1/SLC9A1) is a ubiquitous plasma membrane protein whose main role is maintenance of intracellular pH and volume. NHE-1 plays a role in atherogenesis; however, its clinical relevance has not yet been established.

Areas covered in this review: We herein review the contribution of NHE-1 in atherogenesis (namely its effect on endothelial cells, monocytes, smooth muscle cells and platelets).

What the reader will gain: Studies have shown that NHE is involved in atherogenesis-related properties of isolated monocytes. We also consider the relationship between NHE-1 and vascular risk factors such as obesity, diabetes mellitus, hypertension, dyslipidemia and inflammation.

Take home message: Even though clinical trials with certain NHE-1 inhibitors have had discouraging results, NHE-1 cannot be excluded as a potential future therapeutic target for the prevention and/or treatment of atherosclerosis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Na+ H+交换器-1:与动脉粥样硬化有关?

重点领域:钠/氢交换器-1 (NHE-1/SLC9A1)是一种普遍存在的质膜蛋白，其主要作用是维持细胞内pH和体积。NHE-1在动脉粥样硬化中起作用;然而，其临床相关性尚未建立。本综述涉及的领域:我们在此综述NHE-1在动脉粥样硬化中的作用(即其对内皮细胞、单核细胞、平滑肌细胞和血小板的影响)。读者将获得:研究表明，NHE参与分离单核细胞的动脉粥样硬化相关特性。我们还考虑了NHE-1与血管危险因素如肥胖、糖尿病、高血压、血脂异常和炎症的关系。要点:尽管某些NHE-1抑制剂的临床试验结果令人沮丧，但不能排除NHE-1作为预防和/或治疗动脉粥样硬化的潜在治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.